EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dendritic cell‐targeted delivery of antigens using extracellular vesicles for anti‐cancer immunotherapy

Xuan T T Dang, Cao Dai Phung, Claudine Ming Hui Lim, Migara Kavishka Jayasinghe, Jorgen Ang, Thai Tran, Herbert Schwarz, Minh T N Le iD

Cell Proliferation · 2024-07 · 57 (7)

DOI: 10.1111/cpr.13622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Proliferation, online erschienen am 20.03.2024. Verfasst von Xuan T T Dang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Dendritic Cells, Extracellular Vesicles, Immunotherapy, Cancer Vaccines. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National University of Singapore, Ministry of Health, Singapore, Carmine Therapeutics collaboration grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoantigen delivery using extracellular vesicles (EVs) has gained extensive interest in recent years. EVs derived from tumour cells or immune cells have been used to deliver tumour antigens or antitumor stimulation signals. However, potential DNA contamination from the host cell and the cost of large‐scale EV production hinder their therapeutic applications in clinical settings. Here, we develop an antigen delivery platform for cancer vaccines from red blood cell‐derived EVs (RBCEVs) targeting splenic DEC‐205 + dendritic cells (DCs) to boost the antitumor effect. By loading ovalbumin (OVA) protein onto RBCEVs and delivering the protein to DCs, we were able to stimulate and present antigenic OVA peptide onto major histocompatibility complex (MHC) class I, subsequently priming activated antigen‐reactive T cells. Importantly, targeted delivery of OVA using RBCEVs engineered with anti‐DEC‐205 antibody robustly enhanced antigen presentation of DCs and T cell activation. This platform is potentially useful for producing personalised cancer vaccines in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsExtracellular VesiclesImmunotherapyCancer VaccinesOvalbuminAntigens, NeoplasmAnimalsMiceAntigen PresentationMice, Inbred C57BLNeoplasmsHumansLymphocyte ActivationT-Lymphocytes

Substanzen

Cancer VaccinesOvalbuminAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • School of Applied Science, Republic Polytechnic, Woodlands, Singapore.
  • Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Infectious Disease Translational Research Program, National University of Singapore, Singapore, Singapore.
  • Immunology Programme, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Minh T N Le

Förderung

  • National University of Singapore
  • Ministry of Health, Singapore
  • Carmine Therapeutics collaboration grant

Zitieren

APA

Dang, X. T. T., Phung, C. D., Lim, C. M. H., Jayasinghe, M. K., Ang, J., Tran, T., Schwarz, H., & Le, M. T. N. (2024). Dendritic cell‐targeted delivery of antigens using extracellular vesicles for anti‐cancer immunotherapy. Cell Proliferation, 57(7). https://doi.org/10.1111/cpr.13622

Vancouver

Dang XTT, Phung CD, Lim CMH, Jayasinghe MK, Ang J, Tran T, et al. Dendritic cell‐targeted delivery of antigens using extracellular vesicles for anti‐cancer immunotherapy. Cell Proliferation. 2024;57(7). doi:10.1111/cpr.13622

BibTeX
@article{Dang2024,
  author = {Dang, Xuan T T and Phung, Cao Dai and Lim, Claudine Ming Hui and Jayasinghe, Migara Kavishka and Ang, Jorgen and Tran, Thai and Schwarz, Herbert and Le, Minh T N},
  title = {Dendritic cell‐targeted delivery of antigens using extracellular vesicles for anti‐cancer immunotherapy},
  journal = {Cell Proliferation},
  year = {2024},
  volume = {57},
  number = {7},
  doi = {10.1111/cpr.13622}
}
Kostenlos starten →